近年来对卵巢癌分子事件的理解取得了进展，这促使需要修改国际妇产科联合会（FIGO）的分期系统。新的分期系统能够提供更准确的预后信息和更具体的个性化卵巢癌管理指南，比上一次于1988年修订的旧的分期系统更优。特别地，现在认识到卵巢、输卵管和腹膜癌症具有相似的分子特性，应当从整体上予以考虑。因此，在2012年10月，FIGO执行委员会批准了卵巢、输卵管和腹膜癌症的新FIGO分期指南，并在《国际妇产科杂志》[2014年；124：1-5]上发表。对于需要阐明的旧分期系统进行了几次修订，以便进行准确和适当的患者治疗。分期系统的标准化使患者在不同医疗机构之间更顺畅地过渡，提高了医疗管理的沟通和连续性。本文简要回顾和讨论了新旧分期系统之间的差异。

Recent progress in the understanding of the molecular events in ovarian cancer has prompted the need for a revised International Federation of Gynecology and Obstetrics (FIGO) staging system that may provide more accurate prognostic information and more specific guidance on personalized management of ovarian cancer than the older staging system that was last revised in 1988. In particular, it is now realized that cancer of ovary, fallopian tube, and peritoneum share similar molecular characteristics and should be considered collectively. With that, a new FIGO staging guideline for cancer of the ovary, fallopian tube, and peritoneum was approved by the FIGO executive board in October 2012 and published in the International Journal of Gynecology Obstetrics [2014; 124:1-5]. Several revisions have been made to the older staging system that needs to be elucidated so that accurate and appropriate patient care may be practiced.The standardization of the staging system allows for a smoother transition of patient care between institutions and overall better communication and continuity of management.Our article briefly reviews and discusses the differences between the new and the old staging system of 1988.